Literature DB >> 19370608

Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis.

Claire Allen1, Sally Hopewell, Andrew Prentice, Daisy Gregory.   

Abstract

BACKGROUND: Endometriosis is a common gynaecological condition that affects women and can lead to painful symptoms and infertility. It greatly affects women's quality of life, impacting on their careers, everyday activities, sexual and non-sexual relationships, and fertility. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly used first-line treatment for endometriosis.
OBJECTIVES: To assess the effects of NSAIDs used for the management of pain in women with endometriosis compared to placebo, other NSAIDs, other pain management drugs, or no treatment. SEARCH STRATEGY: We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register (April 2008) published in the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), MEDLINE (1966 to April 2008), EMBASE (1980 to April 2008), and the reference lists from relevant publications. Experts in the field were also contacted for information about possible studies. SELECTION CRITERIA: We included all randomized controlled trials (RCTs) describing the use of NSAIDs in the treatment of endometriosis in women of all ages. DATA COLLECTION AND ANALYSIS: Two review authors (CA and SH) independently read and extracted data from each of the included studies. Crossover trials were analysed using the inverse variance method in RevMan to calculate the odds ratio for binary outcomes. MAIN
RESULTS: Two trials were identified but only one trial, with 24 women, was included in the analysis. Comparing NSAIDs (naproxen) to placebo, there was no evidence of a positive effect on pain relief (odds ratio (OR) 3.27, 95% CI 0.61 to 17.69) in women with endometriosis. There was also inconclusive evidence to indicate whether women taking NSAIDs (naproxen) were less likely to require additional analgesia (OR 0.12, 95% CI 0.01 to 1.29) or to experience side effects (OR 0.46, 95% CI 0.09 to 2.47) when compared to placebo. AUTHORS'
CONCLUSIONS: There is inconclusive evidence to show whether or not NSAIDs (naproxen) are effective in managing pain caused by endometriosis. There is no evidence on whether any individual NSAID is more effective than another. As shown in other Cochrane reviews, women using NSAIDs need to be aware of the possibility that these drugs may cause unintended effects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19370608     DOI: 10.1002/14651858.CD004753.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  24 in total

1.  National German Guideline (S2k): Guideline for the Diagnosis and Treatment of Endometriosis: Long Version - AWMF Registry No. 015-045.

Authors:  U Ulrich; O Buchweitz; R Greb; J Keckstein; I von Leffern; P Oppelt; S P Renner; M Sillem; W Stummvoll; R-L De Wilde; K-W Schweppe
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-12       Impact factor: 2.915

Review 2.  Clinical pharmacology of analgesics assessed with human experimental pain models: bridging basic and clinical research.

Authors:  Bruno Georg Oertel; Jörn Lötsch
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

3.  Interdisciplinary S2k Guidelines for the Diagnosis and Treatment of Endometriosis: Short Version - AWMF Registry No. 015-045, August 2013.

Authors:  U Ulrich; O Buchweitz; R Greb; J Keckstein; I von Leffern; P Oppelt; S P Renner; M Sillem; W Stummvoll; K-W Schweppe
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-09       Impact factor: 2.915

Review 4.  Endometriosis: an overview of Cochrane Reviews.

Authors:  Julie Brown; Cindy Farquhar
Journal:  Cochrane Database Syst Rev       Date:  2014-03-10

5.  Altered genome-wide methylation in endometriosis.

Authors:  Hanyia Naqvi; Ysabel Ilagan; Graciela Krikun; Hugh S Taylor
Journal:  Reprod Sci       Date:  2014-04-30       Impact factor: 3.060

6.  Endometriosis impairs bone marrow-derived stem cell recruitment to the uterus whereas bazedoxifene treatment leads to endometriosis regression and improved uterine stem cell engraftment.

Authors:  Sharif Sakr; Hanyia Naqvi; Barry Komm; Hugh S Taylor
Journal:  Endocrinology       Date:  2014-01-31       Impact factor: 4.736

7.  Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model.

Authors:  Jaime Kulak; Catha Fischer; Barry Komm; Hugh S Taylor
Journal:  Endocrinology       Date:  2011-05-17       Impact factor: 4.736

8.  Treatment with bazedoxifene and conjugated estrogens results in regression of endometriosis in a murine model.

Authors:  Hanyia Naqvi; Sharif Sakr; Thomas Presti; Graciela Krikun; Barry Komm; Hugh S Taylor
Journal:  Biol Reprod       Date:  2014-04-16       Impact factor: 4.285

9.  Quality of life and sexual function of women affected by endometriosis-associated pelvic pain when treated with dienogest.

Authors:  S Caruso; M Iraci; S Cianci; E Casella; V Fava; A Cianci
Journal:  J Endocrinol Invest       Date:  2015-09-04       Impact factor: 4.256

10.  Comparative, open-label prospective study on the quality of life and sexual function of women affected by endometriosis-associated pelvic pain on 2 mg dienogest/30 µg ethinyl estradiol continuous or 21/7 regimen oral contraceptive.

Authors:  S Caruso; M Iraci; S Cianci; V Fava; E Casella; A Cianci
Journal:  J Endocrinol Invest       Date:  2016-03-29       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.